Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an update.
Shanghai Henlius Biotech has secured Chinese regulatory approval to expand the indications of its rituximab biosimilar HANLIKANG, adding two combination therapies for adult patients with previously untreated and relapsed or refractory diffuse large B-cell lymphoma who are ineligible for stem cell transplantation. The decision broadens HANLIKANG’s clinical use across non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis, strengthening the company’s oncology franchise in a domestic rituximab market worth about RMB3.465 billion and offering more treatment options for lymphoma patients in China.
HANLIKANG, already approved in the Chinese Mainland as well as in Nicaragua and Bolivia, can now be combined with polatuzumab vedotin plus chemotherapy in first-line DLBCL and with bendamustine and polatuzumab vedotin in difficult-to-treat relapsed or refractory cases. The expanded label is expected to enhance Henlius’s competitive position in China’s biologics market by leveraging a broader indication spectrum and potentially capturing greater share of the sizeable rituximab segment, benefiting both the company and its stakeholders through increased commercial opportunities and expanded patient access.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$99.78 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a Chinese biopharmaceutical company focused on developing and commercializing therapeutic biological products, including biosimilars such as rituximab. Its flagship rituximab biosimilar, marketed as HANLIKANG, targets oncology and autoimmune indications in the Chinese Mainland and select international markets.
Average Trading Volume: 1,147,828
Technical Sentiment Signal: Buy
Current Market Cap: HK$43.07B
See more data about 2696 stock on TipRanks’ Stock Analysis page.